Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59


Therapeutic considerations for Mdm2: not just a one trick pony.

Lehman JA, Eitel JA, Batuello CN, Mayo LD.

Expert Opin Drug Discov. 2008 Nov;3(11):1309-1321.


MDM2 is a novel E3 ligase for HIV-1 Vif.

Izumi T, Takaori-Kondo A, Shirakawa K, Higashitsuji H, Itoh K, Io K, Matsui M, Iwai K, Kondoh H, Sato T, Tomonaga M, Ikeda S, Akari H, Koyanagi Y, Fujita J, Uchiyama T.

Retrovirology. 2009 Jan 7;6:1. doi: 10.1186/1742-4690-6-1.


MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.

Jin Y, Zeng SX, Sun XX, Lee H, Blattner C, Xiao Z, Lu H.

Mol Cell Biol. 2008 Feb;28(4):1218-29. Epub 2007 Dec 17.


The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.

Kannemeier C, Liao R, Sun P.

Mol Biol Cell. 2007 Jun;18(6):2367-77. Epub 2007 Apr 11.


Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.

LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD.

Cancer Res. 2007 Jan 15;67(2):450-4.


Mornings with Art, lessons learned: feedback regulation, restriction threshold biology, and redundancy govern molecular stress responses.

Bey EA, Wuerzberger-Davis SM, Pink JJ, Yang CR, Araki S, Reinicke KE, Bentle MS, Dong Y, Cataldo E, Criswell TL, Wagner MW, Li L, Gao J, Boothman DA.

J Cell Physiol. 2006 Dec;209(3):604-10. Review.


Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells.

Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD.

J Biol Chem. 2006 Jun 16;281(24):16814-20. Epub 2006 Apr 18.


p53 Activation by small molecules: application in oncology.

Vassilev LT.

J Med Chem. 2005 Jul 14;48(14):4491-9. Review. No abstract available.


ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

Chen D, Kon N, Li M, Zhang W, Qin J, Gu W.

Cell. 2005 Jul 1;121(7):1071-83.


Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor.

Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD, Boothman DA.

J Biol Chem. 2005 Apr 8;280(14):14212-21. Epub 2005 Feb 2.


The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):731-6. Epub 2005 Jan 11.


Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation.

Uchida C, Miwa S, Kitagawa K, Hattori T, Isobe T, Otani S, Oda T, Sugimura H, Kamijo T, Ookawa K, Yasuda H, Kitagawa M.

EMBO J. 2005 Jan 12;24(1):160-9. Epub 2004 Dec 2.


A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ.

Cell. 2004 Nov 24;119(5):591-602.


Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation.

Lu SL, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, Wang XJ.

Cancer Res. 2004 Jul 1;64(13):4405-10.


The ubiquitin ligase COP1 is a critical negative regulator of p53.

Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H, Dixit VM.

Nature. 2004 May 6;429(6987):86-92. Epub 2004 Apr 21.


Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics.

Vassilev LT.

Cell Cycle. 2004 Apr;3(4):419-21. Epub 2004 Apr 1.


In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA.

Science. 2004 Feb 6;303(5659):844-8. Epub 2004 Jan 2.


Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.

Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W.

Science. 2003 Dec 12;302(5652):1972-5.


Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line.

Xie L, Law BK, Aakre ME, Edgerton M, Shyr Y, Bhowmick NA, Moses HL.

Breast Cancer Res. 2003;5(6):R187-98. Epub 2003 Aug 20.

Supplemental Content

Support Center